Company intelligence / Profile preview

Furiex Pharmaceuticals

Morrisville, North Carolina, United Statesbloomberg.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Furiex developed eluxadoline, a locally acting mu opioid receptor agonist/delta antagonist aimed at treating IBS-D symptoms. The company was preparing an NDA submission in late Q3 of 2014. They also advanced JNJ-Q2, a broad-spectrum fluoroquinolone antibiotic licensed from Janssen Pharmaceutica, through successful Phase II trials targeting ABSSSI and CABP[2][4][5].

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Small molecules (e.g., eluxadoline, JNJ-Q2 fluoroquinolone antibiotic)
Industry: Biotech

Drug pipeline

1 asset

avarofloxacin

Phase 2

Indications: Complicated skin and skin structure infections, Community-acquired bacterial pneumonia

Partnerships

Forest Laboratories acquired Furiex in a deal valued at approximately $1.1 billion plus contingent value rights related to eluxadoline’s regulatory status[2][4].Royalty Pharma purchased royalties on other Furiex products like alogliptin and Priligy from Forest post-acquisition[2][4].Janssen Pharmaceutica had licensed out rights to the compound JNJ-Q2 but did not continue development themselves[5].

Beyond the preview

Go deeper on Furiex Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Furiex Pharmaceuticals.

Explore the full profile